Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (736)	9/10/1999 10:40:00 AM
From: timothy alan morris	Read Replies (1) \| Respond to of 849

There is only one test currently in commercial use to screen for cancer via blood - that being the PSA (Prostate Specific Antigen) for detecting and monitoring prostate cancer. There are other cancer markers but they are not useful for screening purposes (CEA for one). The test basically works by finding a specific protein in the blood that is produced only by the tumor. If the protein is detected then you presumably have the tumor (cancer) that is producing the protein. The benefit is that these proteins can be found before other clinical signs or symptoms develop and lead to earlier diagnosis and treatment. If Matritech can succeed in getting a breast cancer screening blood test to market, it would be such a HUGE event it boggles the mind. It would easily be the medical development of the year IMO. For the sake of all the women at risk for this disease, let's hope they're successful. Good luck to all NMPS investors too. Tim